Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1345

Sort by

Sort Order Select

Journal Articles

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda

Blood (2021) 137 (24): 3327–3338.

https://doi.org/10.1182/blood.2020009617

Published: 2021

Includes: Supplemental data

Journal Articles

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Katharina Holstein, Xiaofei Liu, Andrea Smith, Paul Knöbl, Robert Klamroth, Ulrich Geisen, Hermann Eichler, Wolfgang Miesbach, Andreas Tiede

Blood (2020) 136 (3): 279–287.

https://doi.org/10.1182/blood.2019003639

Published: 2020

Includes: Supplemental data

Journal Articles

Hypertension and incident cardiovascular events following ibrutinib initiation

Tyler Dickerson, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Kyle Porter, Devin Haddad, Avirup Guha, Kerry A. Rogers, Seema Bhat, John C. Byrd, Jennifer A. Woyach, Farrukh Awan, Daniel Addison

Blood (2019) 134 (22): 1919–1928.

https://doi.org/10.1182/blood.2019000840

Published: 2019

Includes: Supplemental data

Journal Articles

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Felipe Querol, MD PhD, Sofía Pérez-Alenda, PhD, Juan Eduardo Megias, Juan José Carrasco, MSc, Marta Aguilar, PhD, Saturnino Haya, MD, Ana R Cid, Santiago Bonanad Boix, MD

Blood (2019) 134 (Supplement_1): 2455.

https://doi.org/10.1182/blood-2019-125651

Published: 2019

Journal Articles

Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism

Rachel P Rosovsky, MDMPH, Islam Y Elgendy, MD, Suzanne C Cannegieter, MD PhD, Menno V Huisman, MD PhD, David Jimenez, MD PhD, Jorge del Toro, MD, Vladimir Rosa, MD PhD, Carmen Fernández-Capitán, MD PhD, Alessandra Bura-Riviere, MD PhD, Manuel Monreal, MD PhD

Blood (2019) 134 (Supplement_1): 2429.

https://doi.org/10.1182/blood-2019-131090

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Camila Masias, MDMPH, Rawan Tarawneh, MD, Haiwa Wu, Krista Carter, Shangbin Yang, PhD, Alcinda Flowers, MD, Marie Scully, Spero Cataland, MD

Blood (2019) 134 (Supplement_1): 2377.

https://doi.org/10.1182/blood-2019-130369

Published: 2019

Journal Articles

Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib

Chandler Graf, Anita Sultan, MD, Donald P. Quick, MD, Bradley J. Grant, JD, Sriman Swarup, MDMBBS, Thura Win Htut, MBBS, MRCP, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Sanjay Awasthi, MD, Nicholas D'Cunha, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5876.

https://doi.org/10.1182/blood-2019-123297

Published: 2019

Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4175.

https://doi.org/10.1182/blood-2019-129245

Published: 2019

Journal Articles

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Allison Pike, RN, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5906.

https://doi.org/10.1182/blood-2019-127272

Published: 2019

Journal Articles

Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL)

Zachary West, BS, Kristen Allen, MPH, Caitlin Monroe, MPH, Sharon M. Castellino, MD MSc, Tamara P. Miller, MDMSc

Blood (2019) 134 (Supplement_1): 5809.

https://doi.org/10.1182/blood-2019-131873

Published: 2019

Journal Articles

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Agnès Guerci, MD PhD, Emilie Cayssials, MD, Philippe Rousselot, MD PhD, Francoise Huguet, MD, Valerie Coiteux, MD, Marc G. Berger, MD PhD, Gabriel Etienne, MD PhD, Ali G Turhan, MD PhD

Blood (2019) 134 (Supplement_1): 5908.

https://doi.org/10.1182/blood-2019-122769

Published: 2019

Journal Articles

Retrospective Electronic Medical Records Study of Treatment Patterns Among CLL Patients in the CancerLinQ Research Database

Shaum M Kabadi, PhDMPH, Supriya R Kumar, MS, Jennifer L Wong

Blood (2019) 134 (Supplement_1): 5810.

https://doi.org/10.1182/blood-2019-123014

Published: 2019

Journal Articles

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

Fabio Guolo, MD, Paola Minetto, MD, Luana Fianchi, MD, Michela Rondoni, MD, Giulia Daghia, MD, Stefano D'Ardia, MD, Monica Morselli, MD, Crescenza Pasciolla, MD, Francesca Pavesi, MD, Barbara MD Scappini, Francesco Lanza, MD, Marco Gobbi, MD, Livio Pagano, MD, Felicetto Ferrara, MD, Roberto Massimo Lemoli, MD

Blood (2019) 134 (Supplement_1): 1363.

https://doi.org/10.1182/blood-2019-131329

Published: 2019

Journal Articles

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Neetha Parameswaran, PhD, Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Lisa Durkin, Yvonne Parker, Daniel Lindner, MD PhD, Eric D. Hsi, MD, Deepa Jagadeesh, MDMPH

Blood (2019) 134 (Supplement_1): 1515.

https://doi.org/10.1182/blood-2019-131800

Published: 2019

Journal Articles

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Michelle Janania Martinez, MD, Juan F Garza, MD, Tyler W Snedden, MD, Prathibha Surapaneni, MD, Snegha Ananth, MBBS, Jeremy Rawlings, MD, David J Gregorio, DO, Sushanth Kakarla, MD, Qianqian Liu, PhD, Joel E Michalek, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 2204.

https://doi.org/10.1182/blood-2019-129442

Published: 2019

Journal Articles

An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B Cell Lymphoma

Ahmed Toure, BA, Yiyuan Wu, MS, Paul J Christos, Dr.P.H., M.S., Peter Martin, FRCPC, MD MS

Blood (2019) 134 (Supplement_1): 2205.

https://doi.org/10.1182/blood-2019-131567

Published: 2019

Journal Articles

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Panagiotis Efentakis, PhD, Ioanna Andreadou, PhD, Panagiota-Efstathia Nikolaou, PhD, Claudius Witzler, Svenja Siemer, Eftathios Kastritis, Philip Wenzel, MD PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 3797.

https://doi.org/10.1182/blood-2019-123522

Published: 2019

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

https://doi.org/10.1182/blood-2019-124231

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Hypertension and incident cardiovascular events following ibrutinib initiation

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL)

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Retrospective Electronic Medical Records Study of Treatment Patterns Among CLL Patients in the CancerLinQ Research Database

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B Cell Lymphoma

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only